Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?

Best practice & research. Clinical haematology - 1 Dec 2017

Stone Richard M

Abstract excerpt

For 4 decades, new agents had not been permanently approved for use in treating acute myeloid leukemia (AML). The long dry spell was broken in 2017, however, with the approval of several agents: midostaurin for addition to chemotherapy in mutant FLT3 patients undergoing intensive chemotherapy, enasidenib in advanced mutant IDH2 patients, CPX-351 in secondary AML patients, and gemtuzumab ozogamicin in conjunction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoglycosides
Share to fms-Like Tyrosine Kinase 3
Share to FLT3 gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Staurosporine

Source

Identifiers

PMID: 29156201
DOI: 10.1016/j.beha.2017.09.006

Genes

FLT3
IDH2
KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?PMID 29156201Read ↗

Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid LeukemiaSemantic proximity Read ↗

Contemporary Management of Acute Myeloid Leukemia: A Review.Semantic proximity Read ↗

Updates on targeted therapies for acute myeloid leukaemia.Semantic proximity Read ↗

How I treat acute myeloid leukemia in the era of new drugs.Semantic proximity Read ↗

Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.Semantic proximity Read ↗

An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.Semantic proximity Read ↗

Novel Therapeutics in Acute Myeloid Leukemia.Semantic proximity Read ↗

Recent advances in targeted therapies in acute myeloid leukemia.Semantic proximity Read ↗

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question.Semantic proximity Read ↗

The most novel of the novel agents for acute myeloid leukemia.Semantic proximity Read ↗

Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

[Molecular targeted therapy for acute myeloid leukemia].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.